glp-1 receptor agonists for type 2 diabetes are increasingly used to treat and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal GLP-1 receptor agonist use does

Peer review Peer review information Nature Communications thanks Matteo Villa, and the other, anonymous, reviewer(s) for their contribution to the peer review of this work

Lancet 398(10295):143155

Cysteine is usually the hardest of the three amino acids for the body to find

(Related reading: eHealthcare Solutions discusses how digital pharma marketing shapes drug demand.) Long-Term Uncertainty Although current data is promising, we still lack long-term studies showing the effects of extended GLP-1 drug use over many years

m) Chronic Obstructive Pulmonary Disease (COPD) Oxidative stress can lead to lung tissue damage and inflammation

ACs significantly linked to MDD status and/or depression severity were carried forward in subsequent analyses examining whether the association was mainly driven by specific symptom profiles, by regressing the metabolite levels on each of the three symptom profile scales